proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 6, 1990.

A. **Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Delta Bancshares, Inc.*, Eudora, Arkansas; to engage *de novo* in underwriting credit life and disability insurance, both level and decreasing term, limited to loans to the subsidiary bank's customers pursuant to § 225.25(b)(8)(i) (A) and (B) of the Board's Regulation Y. This activity will be limited to the lending office of the subsidiary bank in Eudora, Arkansas.

Board of Governors of the Federal Reserve System, March 13, 1990.

William W. Wiles,

Secretary of the Board.

[FR Doc. 90-6167 Filed 3-16-90; 8:45 am]

BILLING CODE 6210-01-M

Great River Banshares Corporation, et al.; Formations of; Acquisition by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Banking Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not laer than April 6, 1990.

A. **Federal Reserve Bank of Chicago** (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Great River Bancshares Corporation*, Burlington, Iowa; to become a bank holding company by acquiring 80 percent of the voting shares of Burlington Bank and Trust, Burlington, Iowa.

2. *Hinsbrook Bancshares, Inc.*, Willowbrook, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of Hinsbrook Bank and Trust, Willowbrook, Illinois.

Board of Governors of the Federal Reserve System, March 13, 1990.

William W. Wiles,

Secretary of the Board.

[FR Doc. 90-6168 Filed 3-16-90; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control

Technical Advisory Committee for Diabetes Translation and Community Control Programs: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control (CDC) announces the following committee meeting.

Name: Technical Advisory Committee for Diabetes Translation and Community Control Programs.

Time and Date: 8:30 a.m.—4:30 p.m., Tuesday, April 3, 1990.

Place: St. Anthony Hotel, 300 East Travis Street, San Antonio, Texas 78205.

Status: Open to the public, limited only by the space availble.

Purpose: This committee is charged with advising the Director, CDC, regarding priorities and feasible goals for translation activities and community control programs designed to reduce morbidity and mortality from diabetes and its complications. The Committee advises regarding policies, strategies, goals and objectives, and priorities; identifies research advances and technologies ready for translation into widespread community practice; recommends public health strategies to be implemented through community itnerventions; advises on operational research and outcome evaluation methodologies; identifies research issues for further clinical investigation; and advises regarding the coordination of programs with Federal, voluntary, and private resources involved in the provision of services to people with diabetes.

Matters to be Discussed: The Committee will discuss diabetes translation issues for the 1990s and the status of State-based diabetes control programs. Updates on major projects and initiatives currently underway within the Division of Diabetes Translation (DDT) will be presented. Events and recommendations from the National Diabetes Advisory Board meeting will be summarized.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Frederick G. Murphy, Program Analyst, DDT, Center for Chronic Disease Prevention and Health Promotion, CDC, 1600 Clifton Road, NE., Mailstop E-08, Atlanta, Georgia 30333, telephone—FTS 236-2311; commercial 404/639-2311.

Dated: March 13, 1990.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 90-6206 Filed 3-16-90; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

[Docket No. 90F-0045]

Grain Processing Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: Food and Drug Administration (FDA) is announcing that the Grain Processing Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of alpha-amylase to treat modified food starch.

FOR FURTHER INFORMATION CONTACT: Eric L. Flamm, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-426-8950.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (section 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that the Grain Processing Corp., 1600 Oregon St., P.O. Box 349, Muscatine, IA 52761, has filed a

petition (FAP 9A4153), proposing that the food additive regulations be amended to provide for the safe use of alpha-amylase to treat modified food starch.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 13, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-6192 Filed 3-16-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 87F-0197]

Polysar Ltd.; Filing of Food Additive Petition; Amendment

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending the filing notices for a food additive petition filed by Polysar Ltd. to provide for the safe use of brominated isobutylene-isoprene copolymer as a component of closures with sealing gaskets for food containers and rubber articles for repeated food-contact use, and for the safe use of mixed octylated diphenylamine as a component of brominated and chlorinated isobutylene-isoprene copolymers. Additionally, FDA is announcing that Polysar Ltd.'s petition proposes that the food additive regulations be amended to provide for the safe use of mixed octylated diphenylamine as a component of isobutylene-isoprene copolymers for use as components of closures with sealing gaskets for food containers.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of January 26, 1990 (55 FR 2701), FDA amended the filing notice announced on July 10, 1987 (52 FR 26088). The January 26, 1990 notice stated that a petition (FAP 7B4000) had been filed by Polysar Ltd., c/o 1150 17th St. NW., Washington, DC 20036, proposing that § 177.1210 *Closures with sealing gaskets for food containers* (21 CFR 177.1210) and § 177.2600 *Rubber articles intended for repeated use* (21 CFR 177.2600) be amended to provide for the safe use of brominated isobutylene-isoprene copolymers. The January 26, 1990, amended filing notice also proposed that § 177.1210 be amended to provide for the safe use of mixed octylated diphenylamine as a component of brominated and chlorinated isobutylene-isoprene copolymers.

Polysar Ltd. further proposed in FAP 7B4000 that § 177.1210 be amended to provide for the safe use of mixed octylated diphenylamine as a component of isobutylene-isoprene copolymers. Because this use of mixed octylated diphenylamine was inadvertently omitted from the January 26, 1990 notice, this revised filing notice is being published.

The agency has previously considered the environmental effects of this action in the amended notice of filing for FAP 7B4000 (55 FR 2701). No new information or comments have been received that would affect the agency's previous determination that there is no significant impact on the human environment and that an environmental impact statement is not required.

Dated: March 9, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-6121 Filed 3-16-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90F-0078]

Sumitomo Chemical America, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sumitomo Chemical America, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5]-undecane as an antioxidant in the manufacturing and processing of polypropylene, complying with 21 CFR 177.1520, intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Lawrence J. Lin, Center for Food Safety and Applied Nutritiion (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (section 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4164) has been filed by Sumitomo Chemical America, Inc., 345 Park Ave., New York, NY 10154, proposing that § 178.2010 Antioxidants and/or stabilizers for polymers (21 CFR 178.2010) be amended to provide for the safe use of 3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5]-undecane as an antioxidant in the manufacturing and processing of polypropylene, complying with § 177.1520 (21 CFR 177.1520), intended for use in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 9, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-6193 Filed 3-16-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90M-0069]

Infrasonics, Inc.; Premarket Approval of HFV Infant Star Ventilator

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Infrasonics, Inc., San Diego, CA, for premarket approval, under the Medical Device Amendments of 1976, of the HFV Infant Start Ventilator (the HFV Star). After reviewing the recommendation of the Anesthesiology and Respiratory Therapy Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of January 19, 1990, of the approval of the application..

DATES: Petitions for administrative review by April 18, 1990.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James E. Dillard, Centers for Devices

and Radiological Health (HFZ–430), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20850, 301–427–1044.

SUPPLEMENTARY INFORMATION: On March 20, 1989, Infrasonics, Inc., San Diego, CA 92121, submitted to CDRH an application for premarket approval of the HFV Star. The HFV Star is indicated for us in ventilating critically ill infants in rescue situations were the probability of survival is poor and where the infants meet all of the following criteria:

1. Are, in the opinion of the attending physician, failing on conventional therapy;

2. Have respiratory distress syndrome complicated by pulmonary air leaks with an active chest tube or have pulmonary interstitial emphysema as evidenced by radiographic data;

3. Have an arterial carbon dioxide concentration ($PaCO_2$) greater than 50 torr and/or an inspired oxygen concentration (FiO_2) equal to or greater than 0.5 to maintain an arterial oxygen concentration (PaO_2) of at least 50 torr;

4. Weigh between 500 and 4,100 grams; and

5. Range from 23 to 41 weeks gestational age.

On July 27, 1989, the Anesthesiology and Respiratory Therapy Devices Panel, an FDA advisory committee, reviewed and recommended approval of the application. On January 19, 1990, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

A copy of all approved labeling is available for public inspection at CDRH—contact James E. Dillard (HFZ–430), address above.

Opportunity for Administrative Review

Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petitoin, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before April 18, 1990 file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: March 7, 1990.

Walter E. Gundaker,

Acting Deputy Director, Center for Devices and Radiological Health.

[FR Doc. 90–6122 Filed 3–16–90; 8:45 am]

BILLING CODE 4160–01–M

Statement of Organization, Functions, and Delegations of Authority

Part H, chapter HF (Food and Drug Administration) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3635, February 25, 1970, as amended most recently in pertinent part at 45 FR 57174 on August 27, 1980) is amended to reflect the transfer of functions in the Food and Drug Administration (FDA).

FDA proposes to transfer the contracts and procurement functions from the Office of Management, National Center for Toxicological Research (NCTR) to the Division of Contracts and Grants Management, Office of Management and Operations (OMO). FDA believes this transfer will ensure consistent Agency policy in the area of contracts and procurement. Functional statements for the Division of Contracts and Grants Management, OMO are sufficient to accomplish this change and will not be republished at this time. The NCTR revised statements are reflected below.

Section HF–B Organization and Functions is amended as follows:

1. Delete subparagraph (q–4) Office of Management (HFT1D) in its entirety and insert a new (q–4) Office of Management reading as follows:

(q–4) *Office of Management (HFT1D).* Advises the Director on technical, administrative, and resource management decisions necessary to accomplish the mission and goals of the Center.

Insures that operational problems impeding effective operation of the Center are identified, evaluated, and solved; provides a focal point for project and program evaluation.

Directs the development of strategic and operational planning programs, including resource management and identification and evaluation of program priorities.

Directs the operation and maintenance of the facilities and equipment required to support Center operations, including planning for renovations and improvements and conversion of Center physical facilities for new toxicological programs.

Directs the allocation of space based on planned needs identified by the Center project tracking system.

Directs the development and execution of the Center budget.

Provides financial management of facility operations, involving funds from several participating government agencies.

Directs Center staff responsible for management services programs including property and supplies, financial management, and general services.

Coordinates the development and issuance of management procedures and directives to assure the efficient performance of Center activities.

Dated: March 5, 1990.

James S. Benson,

Acting Commissioner of Food and Drugs.

[FR Doc. 90–6229 Filed 3–16–90; 8:45 am]

BILLING CODE 4160–01–M